Is there still place for VAD as primary treatment for patients with multiple myeloma who are candidates for high-dose therapy?

In 1984, Barlogie et al. [1] reported for the first time a regimen which was active in approximately one-third of patients with multiple myeloma (MM) refractory to standard alkylating agents. This ...